“Favorable Efficacy, Safety, and Tolerability of Tirbanibulin 1% Ointment for Actinic Keratoses in Adults: Findings from European Academy of Dermatology and Venereology Congress 2022”

https://pubmed.ncbi.nlm.nih.gov/38116638

Tirbanibulin 1% ointment shows favorable efficacy, safety, and tolerability in treating actinic keratoses in adult patients, according to presentations at the European Academy of Dermatology and Venereology Congress 2022.